Home
ALVO
ALVO News

Latest Alvotech (ALVO) News on March 14, 2025

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

2 days ago

Exploring 3 High Growth Tech Stocks In The US Market

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

GlobeNewswire

7 days ago

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

GlobeNewswire

18 days ago

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

GlobeNewswire

21 days ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

GlobeNewswire

21 days ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

GlobeNewswire

24 days ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Pagaya Technologies And 2 Other High Growth Tech Stocks In The US

Simply Wall St.

a month ago

Pagaya Technologies And 2 Other High Growth Tech Stocks In The US

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

GlobeNewswire

2 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%

Simply Wall St.

2 months ago

Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

GlobeNewswire

3 months ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks in the United States

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)

Simply Wall St.

4 months ago

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)

GuruFocus.com

4 months ago

Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements

Alvotech Reports Financial Results for the First Nine Months of 2024

GlobeNewswire

4 months ago

Alvotech Reports Financial Results for the First Nine Months of 2024

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

GlobeNewswire

4 months ago

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

GlobeNewswire

4 months ago

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

GlobeNewswire

4 months ago

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Exploring High Growth Tech Stocks In The US October 2024

Simply Wall St.

4 months ago

Exploring High Growth Tech Stocks In The US October 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

GlobeNewswire

5 months ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

GlobeNewswire

5 months ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

GlobeNewswire

5 months ago

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

GlobeNewswire

5 months ago

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

GlobeNewswire

5 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

High Growth Tech Stocks in the United States to Watch

Simply Wall St.

6 months ago

High Growth Tech Stocks in the United States to Watch

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

GlobeNewswire

6 months ago

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

7 months ago

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Simply Wall St.

7 months ago

Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week

Simply Wall St.

7 months ago

Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

GlobeNewswire

7 months ago

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

GlobeNewswire

7 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

GlobeNewswire

7 months ago

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

GlobeNewswire

8 months ago

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

Alvotech Announces Closing of Private Debt Financing

GlobeNewswire

8 months ago

Alvotech Announces Closing of Private Debt Financing

Alvotech Announces Closing of Private Debt Financing

GlobeNewswire

8 months ago

Alvotech Announces Closing of Private Debt Financing

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

GlobeNewswire

8 months ago

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech Issues New Shares to Holders of Convertible Bonds

GlobeNewswire

8 months ago

Alvotech Issues New Shares to Holders of Convertible Bonds

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

GlobeNewswire

8 months ago

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

GlobeNewswire

9 months ago

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

GlobeNewswire

9 months ago

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

GlobeNewswire

9 months ago

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

9 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

9 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

9 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

9 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

9 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

9 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

9 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

9 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

GlobeNewswire

9 months ago

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

GuruFocus.com

9 months ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

Camber Energy Announces Passing of Director Lawrence Fisher

ACCESSWIRE

9 months ago

Camber Energy Announces Passing of Director Lawrence Fisher

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

GlobeNewswire

9 months ago

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire

9 months ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

Newsfile

9 months ago

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

GlobeNewswire

9 months ago

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

CNW Group

9 months ago

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

CNW Group

9 months ago

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

Alvotech Announces Strategic Refinancing Agreement

GlobeNewswire

9 months ago

Alvotech Announces Strategic Refinancing Agreement

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

GlobeNewswire

9 months ago

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

Brokers Are Upgrading Their Views On Alvotech (NASDAQ:ALVO) With These New Forecasts

Simply Wall St.

10 months ago

Brokers Are Upgrading Their Views On Alvotech (NASDAQ:ALVO) With These New Forecasts

Alvotech First Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Simply Wall St.

10 months ago

Alvotech First Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire

10 months ago

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

Business Wire

10 months ago

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Business Wire

10 months ago

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Alvotech S.A. Annual General Meeting to be held June 7, 2024

GlobeNewswire

10 months ago

Alvotech S.A. Annual General Meeting to be held June 7, 2024

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

GlobeNewswire

10 months ago

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

GlobeNewswire

10 months ago

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

GlobeNewswire

10 months ago

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

GlobeNewswire

10 months ago

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

GlobeNewswire

a year ago

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

GlobeNewswire

a year ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

GlobeNewswire

a year ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Business Wire

a year ago

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

GlobeNewswire

a year ago

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Alvotech Announces Increase in Number of Own Shares

GlobeNewswire

a year ago

Alvotech Announces Increase in Number of Own Shares

Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long

Simply Wall St.

a year ago

Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

GlobeNewswire

a year ago

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

GlobeNewswire

a year ago

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

Alvotech Appoints Interim Chief Quality Officer

GlobeNewswire

a year ago

Alvotech Appoints Interim Chief Quality Officer

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

GlobeNewswire

a year ago

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

GlobeNewswire

a year ago

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

GlobeNewswire

a year ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Business Wire

a year ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

GlobeNewswire

a year ago

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount?

Simply Wall St.

a year ago

Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount?

Ryder (R) Boosts Market Presence With Cardinal Logistics Buyout

Zacks

a year ago

Ryder (R) Boosts Market Presence With Cardinal Logistics Buyout

Are Investors Undervaluing Copa Holdings (CPA) Right Now?

Zacks

a year ago

Are Investors Undervaluing Copa Holdings (CPA) Right Now?

Wolfspeed Reports Financial Results for the Second Quarter of Fiscal Year 2024

Business Wire

a year ago

Wolfspeed Reports Financial Results for the Second Quarter of Fiscal Year 2024

First Financial Bankshares, Inc. Names Keith Morton Executive Vice President

PR Newswire

a year ago

First Financial Bankshares, Inc. Names Keith Morton Executive Vice President

Why M.D.C. Holdings, Inc. (MDC) is a Top Dividend Stock for Your Portfolio

Zacks

a year ago

Why M.D.C. Holdings, Inc. (MDC) is a Top Dividend Stock for Your Portfolio

MDC's Q4 Earnings & Revenues Beat, Net New Orders Surge 697%

Zacks

a year ago

MDC's Q4 Earnings & Revenues Beat, Net New Orders Surge 697%

WaFd (WAFD)-Luther Burbank (LBC) Merger Gets Regulatory Nod

Zacks

a year ago

WaFd (WAFD)-Luther Burbank (LBC) Merger Gets Regulatory Nod

Avnet Inc (AVT) Reports Q2 2024 Earnings: Sales Dip Amid Economic Challenges

GuruFocus.com

a year ago

Avnet Inc (AVT) Reports Q2 2024 Earnings: Sales Dip Amid Economic Challenges

B2Gold Announces Positive Exploration Drilling Results from the Antelope Deposit at the Otjikoto Mine in Namibia, Highlighting the Potential to Expand Underground Gold Production through the Early 2030’s

GlobeNewswire

a year ago

B2Gold Announces Positive Exploration Drilling Results from the Antelope Deposit at the Otjikoto Mine in Namibia, Highlighting the Potential to Expand Underground Gold Production through the Early 2030’s

MicroStrategy Inc Executive Chairman, Michael Saylor, Sells 5,000 Shares

GuruFocus.com

a year ago

MicroStrategy Inc Executive Chairman, Michael Saylor, Sells 5,000 Shares

Dentsply Sirona to Host Fourth Quarter and Full Year 2023 Conference Call on February 29th

GlobeNewswire

a year ago

Dentsply Sirona to Host Fourth Quarter and Full Year 2023 Conference Call on February 29th

Blackbaud Announces Date of Fourth Quarter and Full Year 2023 Financial Results

PR Newswire

a year ago

Blackbaud Announces Date of Fourth Quarter and Full Year 2023 Financial Results

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

Motley Fool

a year ago

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

GlobeNewswire

a year ago

Simplicity Group Unveils WeDYOR: Transforming Due Diligence for Crypto Investments

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

GlobeNewswire

a year ago

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

Share on Social Networks: